Adma Biologics (ADMA) Change in Accured Expenses (2011 - 2026)

Adma Biologics (ADMA) has 13 years of Change in Accured Expenses data on file, last reported at -$395000.0 in Q4 2025.

• Quarterly Change in Accured Expenses fell 244.69% year-over-year to -$395000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.2 million (down 269.79% YoY) and the FY2025 annual result came in at -$1.2 million, down 269.79% from the prior year.
• Change in Accured Expenses retreated to -$395000.0 in Q4 2025, from -$234000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $6.1 million in Q2 2023 to a low of -$5.9 million in Q2 2024.
• A 5-year average of -$79000.0 and a median of -$32992.0 in 2021 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses sank 5213.88% — and 2024, when it surged 4081.48%.
• Tracing ADMA's Change in Accured Expenses over 5 years: stood at -$5.3 million in 2021, then surged by 97.43% to -$136585.0 in 2022, then sank by 4046.14% to -$5.7 million in 2023, then soared by 104.82% to $273000.0 in 2024, then tumbled by 244.69% to -$395000.0 in 2025.
• The last three Change in Accured Expenses figures came in at -$395000.0 (Q4 2025), -$234000.0 (Q3 2025), and $48000.0 (Q2 2025), per Business Quant data.